KR20230167077A - 세프티부텐 투여 요법 - Google Patents
세프티부텐 투여 요법 Download PDFInfo
- Publication number
- KR20230167077A KR20230167077A KR1020237037971A KR20237037971A KR20230167077A KR 20230167077 A KR20230167077 A KR 20230167077A KR 1020237037971 A KR1020237037971 A KR 1020237037971A KR 20237037971 A KR20237037971 A KR 20237037971A KR 20230167077 A KR20230167077 A KR 20230167077A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- alkyl
- ceftibuten
- group
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170936P | 2021-04-05 | 2021-04-05 | |
| US63/170,936 | 2021-04-05 | ||
| PCT/US2022/071479 WO2022217199A1 (en) | 2021-04-05 | 2022-03-31 | Ceftibuten dosing regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230167077A true KR20230167077A (ko) | 2023-12-07 |
Family
ID=83545863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237037971A Withdrawn KR20230167077A (ko) | 2021-04-05 | 2022-03-31 | 세프티부텐 투여 요법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197750A1 (enExample) |
| EP (1) | EP4319760A4 (enExample) |
| JP (1) | JP2024512793A (enExample) |
| KR (1) | KR20230167077A (enExample) |
| CN (1) | CN117157078A (enExample) |
| AU (1) | AU2022254114A1 (enExample) |
| BR (1) | BR112023020348A2 (enExample) |
| CA (1) | CA3212788A1 (enExample) |
| MX (1) | MX2023011483A (enExample) |
| TW (1) | TW202304430A (enExample) |
| WO (1) | WO2022217199A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170252351A1 (en) * | 2015-01-24 | 2017-09-07 | Wockhardt Limited | Antibacterial Compositions |
| AU2017290060B2 (en) * | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| AU2017295866A1 (en) * | 2016-07-14 | 2019-01-17 | Achaogen, Inc. | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections |
| SG11201901658PA (en) * | 2016-09-16 | 2019-04-29 | Entasis Therapeutics Ltd | Beta-lactamase inhibitor compounds |
| US10085999B1 (en) * | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| WO2019093450A1 (ja) * | 2017-11-10 | 2019-05-16 | 塩野義製薬株式会社 | ジアザビシクロオクタン誘導体 |
| DK3886798T3 (da) * | 2018-11-29 | 2026-04-20 | Basilea Pharmaceutica Int Ag Allschwil | Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf |
| US12636297B2 (en) * | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP4021443A1 (en) * | 2019-08-29 | 2022-07-06 | Arixa Pharmaceuticals, Inc. | Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections |
-
2022
- 2022-03-31 EP EP22785621.8A patent/EP4319760A4/en active Pending
- 2022-03-31 US US18/553,769 patent/US20240197750A1/en active Pending
- 2022-03-31 BR BR112023020348A patent/BR112023020348A2/pt unknown
- 2022-03-31 KR KR1020237037971A patent/KR20230167077A/ko not_active Withdrawn
- 2022-03-31 JP JP2023561040A patent/JP2024512793A/ja active Pending
- 2022-03-31 AU AU2022254114A patent/AU2022254114A1/en not_active Abandoned
- 2022-03-31 CA CA3212788A patent/CA3212788A1/en active Pending
- 2022-03-31 WO PCT/US2022/071479 patent/WO2022217199A1/en not_active Ceased
- 2022-03-31 MX MX2023011483A patent/MX2023011483A/es unknown
- 2022-03-31 CN CN202280024764.7A patent/CN117157078A/zh active Pending
- 2022-04-01 TW TW111112897A patent/TW202304430A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023011483A (es) | 2023-10-03 |
| US20240197750A1 (en) | 2024-06-20 |
| EP4319760A1 (en) | 2024-02-14 |
| TW202304430A (zh) | 2023-02-01 |
| WO2022217199A1 (en) | 2022-10-13 |
| CN117157078A (zh) | 2023-12-01 |
| CA3212788A1 (en) | 2022-10-13 |
| AU2022254114A1 (en) | 2023-09-21 |
| EP4319760A4 (en) | 2025-01-08 |
| BR112023020348A2 (pt) | 2023-11-21 |
| JP2024512793A (ja) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240197750A1 (en) | Ceftibuten dosing regimens | |
| KR20190117790A (ko) | 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도 | |
| KR20010015890A (ko) | 신경변성질환 치료약 | |
| US20010006972A1 (en) | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome | |
| CN112166111A (zh) | 治疗纤维化疾病的方法 | |
| EP1443933B1 (en) | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents | |
| EP0873753A1 (en) | Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome | |
| US20250325503A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| JP5339840B2 (ja) | 抗ｘｄｒ−ｔｂ薬、抗ｍｄｒ−ｔｂ薬、及び併用抗結核薬 | |
| JP2002537255A (ja) | リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用 | |
| CA2263325A1 (en) | Pharmaceutical compositions comprising tyrphostins | |
| JPS59206309A (ja) | 急発作障害の処置及びそれに有用な製薬組成物 | |
| AU2021220445B2 (en) | Novel medicament for treating hepatic encephalopathy | |
| JPH0152366B2 (enExample) | ||
| JP6908936B2 (ja) | セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤 | |
| WO1999063989A1 (fr) | Traitements de l'ataxie spinocerebelleuse et compositions utiles pour traiter l'ataxie spinocerebelleuse | |
| US20240075041A1 (en) | Treatment of eosinophilic disorders with avapritinib | |
| JP2780115B2 (ja) | 虚血性脳細胞障害に対する細胞保護剤 | |
| WO2018016596A1 (ja) | ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤 | |
| US11400096B2 (en) | Small molecules for the treatment of autoimmune disorders | |
| HK40078840A (en) | Novel medicament for treating hepatic encephalopathy | |
| CA3032858C (en) | Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity | |
| CN120035442A (zh) | 治疗尘肺病的方法 | |
| Ellis | Drugs used in tuberculosis and leprosy | |
| JPWO1993023066A1 (ja) | 血小板数増強剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B11 | Application withdrawn |
Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |